Learn more

Learn more

Learn more

What we do

Omixon is a global biotechnology company that commercializes disruptive innovations specializing in targeted applications for Next Generation Sequencing (NGS). The Omixon Holotype HLA™ product combines a targeted HLA Assay and the Omixon HLA Twin™ software to deliver the most accurate high-resolution HLA genotyping available. Omixon maintains an active grant-funded research program and assists scientists and clinicians to analyze the most challenging genomic regions including HLA, KIR and ABO.

Testimonials

“Together with Omixon, we have now used next- generation sequencing tools to significantly advance HLA typing.”
Prof. Dimitri Monos,The Children’s Hospital of Philadelphia

“We are using next-generation sequencing techniques to advance patient care at Almac and we know that accurate data and meaningful data interpretation are dependent upon employing the best analysis tools and techniques.”
Gavin Oliver,Bioinformatics Team Leader at Almac

“Omixon has developed an excellent direct genotyping method from next generation sequencing that addresses the major problems associated with HLA calling.”
Wolfgang Daum,CEO of Knome

“NGS is rapidly being adopted by clinical and research laboratories worldwide. Easy to use analytical methods and software tools that aid the generation of accurate results are critical for the success of this ground breaking new technology.”
Dr Lajos Pusztai,Professor at the University of Texas MD
Anderson Cancer Center

“Omixon was also the strongest performer in terms of total mutations detected with a 99.14% detection sensitivity in single end mode.”
Gavin Oliver,F1000 Research, 1:2

“Omixon have developed industry-leading capabilities that we are very pleased to be able to incorporate into the informatics pipeline that powers our interpretation services offerings.”
Wolfgang Daum,CEO of Knome

EFI 2015, Success for All We had a tremendous experience last week in the amazingly picturesque city of Geneva Switzerland – the backdrop for EFI 2015, facilitated by Prof. Jean-Marie Tiercy and Dr. Jean Villard and their team of professional …more